DGIdb - BIRC5 Gene Record

BIRC5 332 Druggable GenomeDrug Resistance

Alternate Names:

332
BACULOVIRAL IAP REPEAT CONTAINING 5
BIRC5
API4
EPR-1
603352
593
ENSG00000089685
OTTHUMG00000177505
O15392
355
APOPTOSIS INHIBITOR SURVIVIN
T02677
IAP4

Gene Info:

Target Class	Miscellaneous
Target Subclass	Inhibitor of apoptosis
Gene Biotype	PROTEIN_CODING

(6 More Sources)

Gene Categories: Category Details

TUMOR SUPPRESSOR
DRUG RESISTANCE
PROTEASE INHIBITOR
DRUGGABLE GENOME

Publications:

Qiu et al., 2005, Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death., Int. J. Oncol.
Zhang et al., 2004, [Alteration of survivin gene expression in ovarian cancer cell line CAOV3 after chemotherapy in vitro]., Zhonghua Fu Chan Ke Za Zhi
Zhang et al., 2005, Survivin mediates resistance to antiandrogen therapy in prostate cancer., Oncogene
Thomas et al., 2005, Calcitonin induces apoptosis resistance in prostate cancer cell lines against cytotoxic drugs via the Akt/survivin pathway., Cancer Biol. Ther.
Meng, 2005, [Sensitivity of survivin-positive primary leukemia cells to chemotherapy]., Zhongguo Shi Yan Xue Ye Xue Za Zhi
Carter et al., 2001, Cytokine-regulated expression of survivin in myeloid leukemia., Blood
Peñuelas et al., 2005, Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells., FEBS J.
Yamaguchi et al., 2005, Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death., Oncol. Rep.
He et al., 2006, Expression of survivin gene in apoptosis induced by dexamethasone in CEM cells., Zhongguo Dang Dai Er Ke Za Zhi
Pyrko et al., 2006, Downregulation of survivin expression and concomitant induction of apoptosis by celecoxib and its non-cyclooxygenase-2-inhibitory analog, dimethyl-celecoxib (DMC), in tumor cells in vitro and in vivo., Mol. Cancer
Konturek et al., 2003, Influence of COX-2 inhibition by rofecoxib on serum and tumor progastrin and gastrin levels and expression of PPARgamma and apoptosis-related proteins in gastric cancer patients., Dig. Dis. Sci.
Shankar et al., 2004, UCN-01 alters phosphorylation of Akt and GSK3beta and induces apoptosis in six independent human neuroblastoma cell lines., J. Neurochem.
Ozisik et al., 2006, Expression of antiapoptotic survivin and aven genes in rat heart tissue after traumatic brain injury., Transplant. Proc.
Blanc-Brude et al., 2007, IAP survivin regulates atherosclerotic macrophage survival., Arterioscler. Thromb. Vasc. Biol.
Estève et al., 2007, Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells., J. Biol. Chem.
Minderman et al., 2005, In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells., Mol. Cancer Ther.
Xue et al., 2005, [Factors regulating expression of antiapoptosis gene survivin]., Zhongguo Shi Yan Xue Ye Xue Za Zhi
Guan et al., 2006, [siRNA against survivin coupling with epirubicin enhances to induce breast cancer cell MCF-7 to apoptosis]., Sichuan Da Xue Xue Bao Yi Xue Ban
Pratt et al., 2003, Differential regulation of protein expression, growth and apoptosis by natural and synthetic retinoids., J. Cell. Biochem.
Xia et al., 2006, Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers., Cancer Res.
Jin et al., 2006, Synergistic induction of apoptosis by sulindac and arsenic trioxide in human lung cancer A549 cells via reactive oxygen species-dependent down-regulation of survivin., Biochem. Pharmacol.
Sakoguchi-Okada et al., 2007, Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells., Biochem. Pharmacol.
Sato et al., 2004, FR901228, a novel histone deacetylase inhibitor, induces cell cycle arrest and subsequent apoptosis in refractory human pancreatic cancer cells., Int. J. Oncol.
Morgillo et al., 2006, Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib., Cancer Res.
Hayun et al., 2006, The immunomodulator AS101 induces growth arrest and apoptosis in multiple myeloma: association with the Akt/survivin pathway., Biochem. Pharmacol.
Taguchi et al., 2006, Suppressive effects of dehydroepiandrosterone and the nuclear factor-kappaB inhibitor parthenolide on corticotroph tumor cell growth and function in vitro and in vivo., J. Endocrinol.
Ma et al., 2007, [Effects of Genistein on the proliferation and expression of survivin in salivary adenoid cystic carcinoma cell line SACC-83]., Hua Xi Kou Qiang Yi Xue Za Zhi
Kirkiles-Smith et al., 2004, IL-11 protects human microvascular endothelium from alloinjury in vivo by induction of survivin expression., J. Immunol.
Kulp et al., 2006, Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer., Clin. Cancer Res.
Chakrabarty et al., 2013, Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors., Cancer Res.
Aziz et al., 2005, Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease?, FASEB J.
Fulda et al., 2004, Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol., Cancer Res.
Carter et al., 2006, Regulation of survivin expression through Bcr-Abl/MAPK cascade: targeting survivin overcomes imatinib resistance and increases imatinib sensitivity in imatinib-responsive CML cells., Blood
de Angelis et al., 2004, Molecular characterizations of derivatives of HCT116 colorectal cancer cells that are resistant to the chemotherapeutic agent 5-fluorouracil., Int. J. Oncol.

GATAPARSEN BIRC5

Interaction Score: 3.43

Interaction Types & Directionality:

antisense oligonucleotide (inhibitory)

Interaction Info:

Novel drug target Novel Target

Trial Name LY2181308

Notes

PMIDs:
None found

Sources:
TALC TdgClinicalTrial
VALDECOXIB BIRC5

Interaction Score: 1.72

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16707021

Sources:
NCI
AMMONIUM TRICHLOROTELLURATE BIRC5

Interaction Score: 1.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16889755

Sources:
NCI
OMACETAXINE MEPESUCCINATE BIRC5

Interaction Score: 0.86

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15854289

Sources:
NCI
ROFECOXIB BIRC5

Interaction Score: 0.74

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16707021 14627349

Sources:
NCI
OPRELVEKIN BIRC5

Interaction Score: 0.57

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14734714

Sources:
NCI
PLICAMYCIN BIRC5

Interaction Score: 0.57

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17124180

Sources:
NCI
CALCITONIN BIRC5

Interaction Score: 0.57

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16222118

Sources:
NCI
IRINOTECAN HYDROCHLORIDE BIRC5

Interaction Score: 0.49

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15956246

Sources:
NCI
TRASTUZUMAB BIRC5

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23204226 16452223

Sources:
NCI CIViC
SULINDAC BIRC5

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16950207 16707021

Sources:
NCI
REGRAMOSTIM BIRC5

Interaction Score: 0.23

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16403261

Sources:
NCI
PRASTERONE BIRC5

Interaction Score: 0.19

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16461558

Sources:
NCI
ROMIDEPSIN BIRC5

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14767553

Sources:
NCI
EPOETIN ALFA BIRC5

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17112829

Sources:
NCI
FLUTAMIDE BIRC5

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15735703

Sources:
NCI
TRETINOIN BIRC5

Interaction Score: 0.18

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16403261 14587026

Sources:
NCI
UCN-01 BIRC5

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15255949

Sources:
NCI
RESVERATROL BIRC5

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17270149 15837718 14729643

Sources:
NCI
LAPATINIB BIRC5

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16452223

Sources:
NCI
STAUROSPORINE BIRC5

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17255535

Sources:
NCI
EPIRUBICIN BIRC5

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16608080

Sources:
NCI
INDOMETHACIN BIRC5

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17270149

Sources:
NCI
CAMPTOTHECIN BIRC5

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16211302

Sources:
NCI
CHEMBL35482 BIRC5

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11313272

Sources:
NCI
VORINOSTAT BIRC5

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16951239

Sources:
NCI
ERLOTINIB BIRC5

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17047074

Sources:
NCI
PACLITAXEL BIRC5

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16211241 15347474

Sources:
ClearityFoundationBiomarkers NCI
GENISTEIN BIRC5

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17375591

Sources:
NCI
IMATINIB BIRC5

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16254145

Sources:
NCI
CARBOPLATIN BIRC5

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15347474

Sources:
NCI
DEXAMETHASONE BIRC5

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16787583

Sources:
NCI
DOXORUBICIN BIRC5

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16211302

Sources:
NCI
FLUOROURACIL BIRC5

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15067352

Sources:
NCI
METHOTREXATE BIRC5

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15670151

Sources:
NCI
DOCETAXEL BIRC5

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
ClearityFoundationBiomarkers

Ensembl: ENSG00000089685
- Version: 101_38
Alternate Names:

BIRC5 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
TdgClinicalTrial: O15392
- Version: January-2014
Alternate Names:

BIRC5 Gene Symbol

Gene Info:

Target Class Miscellaneous

Target Subclass Inhibitor of apoptosis

Publications:

CIViC: BIRC5

Version: 14-September-2020

Alternate Names:

332 Entrez Gene ID

355 CIViC Gene ID

Gene Info:

Gene Categories:

DRUG RESISTANCE

Publications:

Wu et al., 2014, Nuclear survivin expression: a prognostic factor for the response to taxane-platinum chemotherapy in patients with advanced non-small cell lung cancer., Med. Oncol.

Chakrabarty et al., 2013, Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors., Cancer Res.

NCI: BIRC5

Version: 14-September-2017

Alternate Names:

Gene Info:

Publications:

Thomas et al., 2005, Calcitonin induces apoptosis resistance in prostate cancer cell lines against cytotoxic drugs via the Akt/survivin pathway., Cancer Biol. Ther.

Peñuelas et al., 2005, Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells., FEBS J.

Ozisik et al., 2006, Expression of antiapoptotic survivin and aven genes in rat heart tissue after traumatic brain injury., Transplant. Proc.

TALC: BIRC5
- Version: 12-May-2016
Alternate Names:

BIRC5 Gene Symbol

Gene Info:

Publications:
HingoraniCasas: ENSG00000089685
- Version: 31-May-2017
Alternate Names:

ENSG00000089685 Gene Symbol

BIRC5 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
GO: BIRC5
- Version: 01-February-2022
Alternate Names:

API4 GO Gene Synonym

IAP4 GO Gene Synonym

Gene Info:

Gene Categories:

TUMOR SUPPRESSOR

Publications:
dGene: BIRC5
- Version: 27-Jun-2013
Alternate Names:

332 Gene ID

API4 dGene Synonym

EPR-1 dGene Synonym

Gene Info:

Gene Categories:

PROTEASE INHIBITOR

Publications:
TTD: Apoptosis inhibitor survivin
- Version: 2020.06.01
Alternate Names:

BIRC5 TTD Gene Abbreviation

T02677 TTD Target ID

Gene Info:

Publications:
ClearityFoundationBiomarkers: BIRC5
- Version: 26-July-2013
Alternate Names:

Gene Info:

Publications:

Novel drug target	Novel Target
Trial Name	LY2181308
Notes

BIRC5 Gene Record

BIRC5 332 Druggable GenomeDrug Resistance

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: antisense oligonucleotide (inhibitory)

Interaction Info: Novel drug target Novel Target Trial Name LY2181308 Notes

PMIDs: None found

Sources: TALC TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16707021

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16889755

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15854289

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16707021 14627349

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14734714

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17124180

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16222118

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15956246

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 23204226 16452223

Sources: NCI CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16950207 16707021

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16403261

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16461558

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14767553

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 17112829

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15735703

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16403261 14587026

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15255949

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

Interaction Types & Directionality:

antisense oligonucleotide (inhibitory)

Interaction Info:

Novel drug target Novel Target

Trial Name LY2181308

Notes

PMIDs:
None found

Sources:
TALC TdgClinicalTrial

Interaction Types & Directionality:

n/a

PMIDs:
16707021

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16889755

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15854289

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16707021 14627349

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
14734714

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17124180

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16222118

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15956246

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
23204226 16452223

Sources:
NCI CIViC

Interaction Types & Directionality:

n/a

PMIDs:
16950207 16707021

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16403261

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16461558

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
14767553

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17112829

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15735703

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16403261 14587026

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
15255949

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17270149 15837718 14729643

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16452223

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17255535

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16608080

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17270149

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16211302

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11313272

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
16951239

Sources:
NCI

Interaction Types & Directionality:

n/a